NBIX - FDA sets target action dates for Neurocrine drug applications
2024-07-01 11:55:27 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
- Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
- Neurocrine Biosciences CEO Gorman stepping down in October
- Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences